Global Rivaroxaban Market to reach 11 Bn US$ by 2025 at 8.2% CAGR- Bayer, J&J

The global Rivaroxaban market is valued at 5.86 billion USD in 2018 and is expected to reach 11 billion USD by the end of the year 2025, growing at a CAGR of 8.2%.

Dublin, United States - February 22, 2019 /MarketersMedia/ —

The global Rivaroxaban market is valued at 5.86 billion USD in 2018 and is expected to reach 11 billion USD by the end of the year 2025, growing at a CAGR of 8.2%. Rivaroxaban is an oral anti-coagulant approved for the treatment of pulmonary embolism, stroke prevention in non-valvular atrial fibrillation, prevention of recurrent venous thromboembolism (VTE), and deep vein thrombosis.

Get Sample of This Report Spread Across 114 Pages And 02 Companies At https://inforgrowth.com/samplerequest/r/987153/qyresearchglobal-rivaroxaban-market-insights-forecast-to-2025

The drug is sold under the brand name Xarelto. The drug, initially developed by Bayer, is marketed by Janssen Pharmaceuticals in the United States. The average selling price of the drug in the global market has witnessed a decreasing trend, from 5.62 USD/unit in 2011 to 5.34 USD/Unit in 2015. This decreasing price trend is expected to continue for the next 5 years. On the basis of product, the global rivaroxaban market has been segmented into 2.5 mg, 10mg, 15mg, and 20mg.

The dreadful bleeding-related injuries caused by the drug have led the companies to face many lawsuits, specifically in the US market. The injuries caused by the use of Xarelto can be gastrointestinal, cerebral, and other types of bleeding. The companies have around 21,400 lawsuits against them pending in the state and federal courts in the US. All these factors are expected to negatively impact the rivaroxaban market. Another factor that may impede market growth is the patent expiration of this drug that is slated to occur during the forecast period.

Key Players covered in this report are Bayer, J&J.
Rivaroxaban Market is analyzed by types like 2.5 mg, 10 mg, 15 mg, 20 mg.
Rivaroxaban Market is also analyzed by Application like Acute Coronary Syndrome (ACS), Venous Thromboembolism (VTE).

The study objectives of this report are:
To study and analyze the global Rivaroxaban market size (value & volume) by the company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Rivaroxaban market by identifying its various sub-segments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Rivaroxaban companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Rivaroxaban submarkets, with respect to key regions.

Table of Contents:
1 Study Coverage
2 Executive Summary
3 Breakdown Data by Manufacturers
4 Breakdown Data by Product
5 Breakdown Data by End User
6 North America
7 Europe
8 Asia Pacific
9 Central & South America
10 Middle East and Africa
11 Company Profiles
12 Future Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
14 Value Chain and Sales Channels Analysis
15 Research Findings and Conclusion
And More

Submit Your Details And Specific Interests For All Customization Needs Here https://inforgrowth.com/customizationrequest/r/987153/qyresearchglobal-rivaroxaban-market-insights-forecast-to-2025

Contact Info:
Name: Rohan
Email: Send Email
Organization: InForGrowth
Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USA
Phone: +1-909-329-2808
Website: http://www.inforgrowth.com

Source URL: https://marketersmedia.com/global-rivaroxaban-market-to-reach-11-bn-us-by-2025-at-82-cagr-bayer-jj/485141

Source: MarketersMedia

Release ID: 485141